In our study, we selected a cut-off of 10 mutations/Mb, which in a trial of nivolumab plus ipilimumab in non-small-cell lung cancer-selected patients was most likely to have a response irrespective of tumour PD-L1 expression level [51]. Here, CD274 is linked to non-small cell lung carcinoma.